Type I and II interferon signaling in colorectal cancer liver metastasis. (January 2023)

• Record Type: Journal Article
• Authors: Mödl, Bernadette; Moritsch, Stefan; Zwolanek, Daniela; Eferl, Robert
• Is Part Of: Cytokine. Volume 161(2023)
• Publication Date: 2023-01
• Subjects: Colorectal cancer CRC -- Colorectal cancer liver metastasis CRLM -- Type I interferon -- Type II interferon IFN-γ -- Tumor microenvironment TME; Cytokines -- Periodicals; 571.844
• DOI: 10.1016/j.cyto.2022.156075
• Languages: English
• ISSNs: 1043-4666

Abstract

Abstract: Metastatic colorectal cancer is one of the leading causes of cancer-related deaths worldwide. Traditional chemotherapy extended the lifespan of cancer patients by only a few months, but targeted therapies and immunotherapy prolonged survival and led to long-term remissions in some cases. Type I and II interferons have direct pro-apoptotic and anti-proliferative effects on cancer cells and stimulate anti-cancer immunity. As a result, interferon production by cells in the tumor microenvironment is in the spotlight of immunotherapies as it affects the responses of anti-cancer immune cells. However, promoting effects of interferons on colorectal cancer metastasis have also been reported. Here we summarize our knowledge about pro- and anti-metastatic effects of type I and II interferons in colorectal cancer liver metastasis and discuss possible therapeutic implications.